HomeSHTDY • OTCMKTS
add
Sinopharm Group ADR
Previous close
$11.31
Day range
$11.04 - $11.51
Year range
$10.13 - $16.31
Market cap
55.61B HKD
Avg Volume
22.85K
Market news
Financials
Income Statement
Revenue
Net income
| (CNY) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 144.89B | -3.82% |
Operating expense | 6.44B | 15.96% |
Net income | 1.67B | -43.43% |
Net profit margin | 1.15 | -41.33% |
Earnings per share | — | — |
EBITDA | 5.32B | -35.75% |
Effective tax rate | 29.36% | — |
Balance Sheet
Total assets
Total liabilities
| (CNY) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 54.31B | -19.10% |
Total assets | 392.83B | 2.46% |
Total liabilities | 266.14B | 1.17% |
Total equity | 126.69B | — |
Shares outstanding | 3.12B | — |
Price to book | 0.45 | — |
Return on assets | 3.00% | — |
Return on capital | 5.81% | — |
Cash Flow
Net change in cash
| (CNY) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | 1.67B | -43.43% |
Cash from operations | 26.27B | 43.57% |
Cash from investing | -1.36B | 69.47% |
Cash from financing | -19.42B | -266.23% |
Net change in cash | 5.49B | -78.50% |
Free cash flow | 3.14B | -92.00% |
About
Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical.
Its H shares were listed on the Hong Kong Stock Exchange in 2009, with its IPO price of HK$16 per share. Sinopharm Group's subsidiary Sinopharm CNMC and Sinopharm Accord served as the A share counterpart of the company. However, the A share of Sinopharm Group itself was unlisted.
Sinopharm Group was ranked 829th in 2016 Forbes Global 2000 list. Wikipedia
Founded
2003
Website
Employees
108,217
